Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 9/20 | 0.77 |
| ▸ | MEN1 | O00255 | 7/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.77 |
| ▸ | THRA | P10827 | 5/20 | 0.77 |
| ▸ | LMNA | P02545 | 5/20 | 0.77 |
| ▸ | PPARG | P37231 | 3/20 | 0.77 |
| ▸ | PCNA | P12004 | 2/20 | 0.77 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.77 |
| ▸ | TSHR | P16473 | 1/20 | 0.77 |
| ▸ | GABRP | O00591 | 1/20 | 0.77 |
| ▸ | GABRD | O14764 | 1/20 | 0.77 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.77 |
| ▸ | F2 | P00734 | 1/20 | 0.77 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.77 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.77 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.77 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.77 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.77 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.77 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29651864 | 1.00 | THRB (0.77) | THRBMEN1KMT2ATHRALMNA | |
| SCHEMBL677617 | 1.00 | THRB (0.77) | THRBMEN1KMT2ATHRALMNA | |
| SCHEMBL29135014 | 1.00 | THRB (0.77) | THRBMEN1KMT2ATHRALMNA | |
| SCHEMBL14574802 | 0.90 | THRB (0.70) | THRBMEN1KMT2ATHRALMNA | |
| SCHEMBL14575018 | 0.90 | THRB (0.70) | THRBMEN1KMT2ATHRALMNA | |
| SCHEMBL14574800 | 0.90 | THRB (0.70) | THRBMEN1KMT2ATHRALMNA | |
| SCHEMBL677606 | 0.88 | MEN1 (0.74) | THRBMEN1KMT2ATHRALMNA | |
| SCHEMBL2139921 | 0.88 | MEN1 (0.74) | THRBMEN1KMT2ATHRALMNA | |
| SCHEMBL9619480 | 0.88 | MEN1 (0.74) | THRBMEN1KMT2ATHRALMNA | |
| Diiodothyronine SCHEMBL677645 | 0.87 | MEN1 (0.78) | THRBMEN1KMT2ATHRALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117554536-B | Simultaneous analysis method for 15 thyroid hormones in environmental water sample | 北京林业大学 | 2024-03-19 | — | — | CN | claimed |
| CN-117554536-A | Simultaneous analysis method for 15 thyroid hormones in environmental water sample | 北京林业大学 | 2024-02-13 | — | — | CN | claimed |
| US-20200222348-A1 | BIMODAL MODIFIED RELEASE COMPOSITIONS FOR CANCER TREATMENT | MUSLI THYROPEUTICS LTD. (IL) | 2020-07-16 | — | — | US | claimed |
| EP-3621602-A1 | BIMODAL MODIFIED RELEASE COMPOSITIONS FOR CANCER TREATMENT | Musli Thyropeutics Ltd. (IL) | 2020-03-18 | — | — | EP | claimed |
| WO-2018207171-A1 | BIMODAL MODIFIED RELEASE COMPOSITIONS FOR CANCER TREATMENT | MUSLI THYROPEUTICS LTD. (IL) | 2018-11-15 | — | — | WO | claimed |
| US-20110064773-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A THYROID HORMON AND THEIR THERAPEUTIC USE | UNIVERSITE JOSEPH FOURIER (FR) | 2011-03-17 | — | — | US | claimed |
| US-20110028554-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING DIIODOTHYRONINE AND THEIR THERAPEUTIC USE | UNIVERSITE JOSEPH FOURIER (FR) | 2011-02-03 | — | — | US | claimed |
| EP-2068859-A1 | NEW PHARMACEUTICAL COMPOSITIONS COMPRISING A THYROID HORMON AND THEIR THERAPEUTIC USE | Université Joseph Fourier (FR) | 2009-06-17 | — | — | EP | claimed |
| EP-2068858-A1 | NEW PHARMACEUTICAL COMPOSITIONS COMPRISING DIIODOTHYRONINE AND THEIR THERAPEUTIC USE | Université Joseph Fourier (FR) | 2009-06-17 | — | — | EP | claimed |
| WO-2008138995-A1 | NEW PHARMACEUTICAL COMPOSITIONS COMPRISING A THYROID HORMON AND THEIR THERAPEUTIC USE | UNIVERSITE JOSEPH FOURIER (FR) | 2008-11-20 | — | — | WO | claimed |
| WO-2008138993-A1 | NEW PHARMACEUTICAL COMPOSITIONS COMPRISING DIIODOTHYRONINE AND THEIR THERAPEUTIC USE | UNIVERSITE JOSEPH FOURIER (FR) | 2008-11-20 | — | — | WO | claimed |
| EP-1992341-A1 | New pharmaceutical compositions comprising a thyroid hormon and their therapeutic use | Université Joseph Fourier (FR) | 2008-11-19 | — | — | EP | claimed |
| EP-0093653-B1 | PROCESS FOR THE PREPARATION OF IODO-THYRONINES AND IODO-THYROACETIC ACIDS BY ELECTROCHEMICAL REDUCTION AT A CONTROLLED POTENTIAL | SPIRAL Société à responsabilité limitée dite : (FR) | 1985-07-10 | — | — | EP | claimed |
| US-4490221-A | Process for preparing iodothyronines and iodothyroacetic acids by electrochemical reduction at controlled potential | SPIRAL SOCIETE A RESPONSABILITE LIMITEE DITE (FR) | 1984-12-25 | — | — | US | claimed |
| CN-114609266-B | Application of marker in preparation of diagnostic reagent for thyroid related diseases | 徐州医科大学 | 2023-03-24 | — | — | CN | disclosed |
| EP-3753558-A1 | THYROID HORMONE FOR USE IN THE TREATMENT OF A PERIPHERAL VESTIBULOPATHY | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE -CNRS- (FR) | 2020-12-23 | — | — | EP | disclosed |
| US-20200222348-A1 | BIMODAL MODIFIED RELEASE COMPOSITIONS FOR CANCER TREATMENT | MUSLI THYROPEUTICS LTD. (IL) | 2020-07-16 | — | — | US | disclosed |
| WO-2003025627-A9 | OPTICAL BIOSENSOR WITH ENHANCED ACTIVITY RETENTION FOR DETECTION OF HALOGENATED ORGANIC COMPOUNDS | UNIV COLORADO STATE RES FOUND (US) | 2003-06-19 | — | — | WO | disclosed |
| WO-2003025627-A2 | OPTICAL BIOSENSOR WITH ENHANCED ACTIVITY RETENTION FOR DETECTION OF HALOGENATED ORGANIC COMPOUNDS | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2003-03-27 | — | — | WO | disclosed |
| WO-1996021728-A2 | TRANSGENIC ANIMALS HAVING A DEFECTIVE THYROID HORMONE RECEPTOR GENE | KARO BIO AB (SE) | 1996-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028554-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING DIIODOTHYRONINE AND THEIR THERAPEUTIC USE | TPO, HSD3B2, THRB | THRB 3/4885MEN1 692/4885KMT2A 2483/4885 |
| US-20110064773-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A THYROID HORMON AND THEIR THERAPEUTIC USE | TPO, TSHR, THRA | THRB 5/4885MEN1 301/4885KMT2A 4327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.